ARCHIVES

Two Second-Line CML Drugs Work Front-Line, Studies Find

This article is from The Cancer Letter archive.

Vol. 33 No. 1 | January 29, 2010

Download PDF Visit The Full Archive

Related Articles

Phase II Elotuzumab Study Demonstrates 33 Months PFS

July 26, 2013

Van Nevel New NCI information Chief: Karel Leaves For Johnson Foundation

August 30, 1974

NCI Director Harold Varmus Plans New Center For Cancer Genomics To Lead The Cancer Genome Atlas Program.

September 10, 2010

Cancer Vaccine RFAs Approved In Concept By NCI Advisors

July 26, 1991

Advisors Say 10 Percent Payline “Not Tenable;” All NCI Programs Must Share Budget Cuts.

March 31, 2006

DeVita Frustrated By Gap Between Bypass, “Real” Budgets, Seeks Better System To Develop Priorites

April 24, 1981